Crespi Elisa, Bottai Giulia, Santarpia Libero
Oncology Experimental Therapeutics, IRCCS Humanitas Clinical and Research Center, Rozzano, Milan, Italy.
Oncology Experimental Therapeutics, IRCCS Humanitas Clinical and Research Center, Rozzano, Milan, Italy.
Curr Opin Pharmacol. 2016 Dec;31:114-122. doi: 10.1016/j.coph.2016.11.004. Epub 2016 Nov 24.
Chronic inflammation associated with obesity is now recognized to be an important condition in promoting carcinogenesis and progression in breast cancer patients, mostly in postmenopausal women with tumors expressing estrogen and progesterone receptors. In obese patients, altered levels of several inflammatory mediators regulating aromatase and estrogen expression are one of the mechanisms responsible of increase breast cancer risk. Growing attention has also been paid to the local adipose inflammation and the role played by macrophages as determinants of breast cancer risk recurrence and prognosis. The inflammation-obesity axis offers different molecular signaling pathways for therapeutic interventions and potential pharmacological targets. The increasing rate of obesity worldwide associated with the recent findings linking inflammation and breast cancer urge further investigation.
与肥胖相关的慢性炎症现已被认为是促进乳腺癌患者致癌和病情进展的重要因素，主要发生在肿瘤表达雌激素和孕激素受体的绝经后女性中。在肥胖患者中，几种调节芳香化酶和雌激素表达的炎症介质水平改变是导致乳腺癌风险增加的机制之一。局部脂肪炎症以及巨噬细胞作为乳腺癌风险复发和预后的决定因素所起的作用也越来越受到关注。炎症 - 肥胖轴为治疗干预提供了不同的分子信号通路和潜在的药理学靶点。全球肥胖率的上升以及最近将炎症与乳腺癌联系起来的研究结果促使人们进一步开展研究。
